Chengdu-based WestVac Biopharma Co., Ltd has announced receiving clinical trial approval from the National Medical Products Administration (NMPA) for two COVID-19 protein vaccines co-developed in collaboration with West China Hospital, Sichuan University. These vaccines are specifically targeting the XBB variant and other emerging strains, including the recombinant bivalent COVID-19 protein vaccine (Sf9 cells) and the recombinant trivalent COVID-19 trimeric protein vaccine (Sf9 cells).
Addressing the Dominant XBB Variant in China
The XBB variant has become dominant in China, posing significant public health challenges. The vaccines developed by WestVac Biopharma are designed to induce the production of high-level neutralizing antibodies against various strains, including XBB.1.5, XBB.1.16, XBB.1.9.1, XBB.2.3, BA.5, BF.7, BQ.1, and others. This development is crucial in the ongoing efforts to combat the evolving SARS-CoV-2 virus and protect public health.-Fineline Info & Tech
